DK142802B - Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken. - Google Patents
Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken. Download PDFInfo
- Publication number
- DK142802B DK142802B DK97875AA DK97875A DK142802B DK 142802 B DK142802 B DK 142802B DK 97875A A DK97875A A DK 97875AA DK 97875 A DK97875 A DK 97875A DK 142802 B DK142802 B DK 142802B
- Authority
- DK
- Denmark
- Prior art keywords
- stomach
- parts
- coated
- preparation
- gastric juice
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 23
- 210000002784 stomach Anatomy 0.000 title description 22
- 238000002360 preparation method Methods 0.000 title description 15
- 230000001225 therapeutic effect Effects 0.000 title description 11
- 238000000034 method Methods 0.000 title description 10
- 239000004480 active ingredient Substances 0.000 description 17
- 210000004051 gastric juice Anatomy 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- 239000001856 Ethyl cellulose Substances 0.000 description 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 10
- 235000019325 ethyl cellulose Nutrition 0.000 description 10
- 229920001249 ethyl cellulose Polymers 0.000 description 10
- ZEEXVYNJSAWEML-UHFFFAOYSA-N 3-[4-(4-methylphenyl)sulfanyl-3-nitrophenyl]prop-2-enoic acid Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C=CC(O)=O)C=C1[N+]([O-])=O ZEEXVYNJSAWEML-UHFFFAOYSA-N 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 9
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 9
- 229960001377 benactyzine hydrochloride Drugs 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 241000209094 Oryza Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 4
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 3
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920006327 polystyrene foam Polymers 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 241001342895 Chorus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2767374 | 1974-03-12 | ||
| JP2767374A JPS5512411B2 (cs) | 1974-03-12 | 1974-03-12 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK97875A DK97875A (cs) | 1975-09-13 |
| DK142802B true DK142802B (da) | 1981-02-02 |
| DK142802C DK142802C (cs) | 1981-09-21 |
Family
ID=12227459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97875AA DK142802B (da) | 1974-03-12 | 1975-03-11 | Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US3976764A (cs) |
| JP (1) | JPS5512411B2 (cs) |
| BE (1) | BE826498A (cs) |
| CA (1) | CA1054056A (cs) |
| CH (1) | CH604719A5 (cs) |
| DE (1) | DE2510620C2 (cs) |
| DK (1) | DK142802B (cs) |
| ES (1) | ES435500A1 (cs) |
| FR (1) | FR2263744B1 (cs) |
| GB (1) | GB1507521A (cs) |
| NL (1) | NL7502952A (cs) |
| SE (1) | SE409286B (cs) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003437A1 (en) * | 1984-02-10 | 1985-08-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH630257A5 (en) * | 1975-03-17 | 1982-06-15 | Hoffmann La Roche | Sustained release formulation |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4207890A (en) * | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
| JPS6024767B2 (ja) * | 1979-08-24 | 1985-06-14 | 塩野義製薬株式会社 | 腸溶性硬カプセル剤 |
| ATE34300T1 (de) * | 1981-07-15 | 1988-06-15 | Key Pharma | Theophyllin mit verlaengerter abgabe. |
| US4451260A (en) * | 1982-03-26 | 1984-05-29 | Minnesota Mining And Manufacturing Company | Sustained release oral medicinal delivery device |
| JPS5953410A (ja) * | 1982-09-20 | 1984-03-28 | Fujisawa Pharmaceut Co Ltd | 新型ソフトカプセル剤 |
| JPS59193831A (ja) * | 1983-04-18 | 1984-11-02 | Sankyo Co Ltd | 腸溶性製剤の製造法 |
| US4505890A (en) * | 1983-06-30 | 1985-03-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation and method |
| SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| JPS61107782U (cs) * | 1984-12-19 | 1986-07-08 | ||
| US4735804A (en) * | 1985-05-10 | 1988-04-05 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4758436A (en) * | 1985-05-29 | 1988-07-19 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4767627A (en) * | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4666705A (en) * | 1985-06-03 | 1987-05-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4814178A (en) * | 1987-07-01 | 1989-03-21 | Sanford Bolton | Floating sustained release therapeutic compositions |
| DE3803482A1 (de) * | 1988-02-05 | 1989-08-17 | Lohmann Therapie Syst Lts | Schwimmfaehiges orales therapeutisches system |
| JPH082781B2 (ja) * | 1988-10-18 | 1996-01-17 | 嘉明 川島 | 中空顆粒状医薬及びその製法 |
| JPH05507717A (ja) * | 1990-06-25 | 1993-11-04 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | 軟ゼラチンカプセル剤中で使用するための高められた溶解特性を有するアマンタジン塩酸塩懸濁液 |
| US5232704A (en) * | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
| US5198229A (en) * | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
| US5314696A (en) * | 1991-06-27 | 1994-05-24 | Paulos Manley A | Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor |
| DE4406424A1 (de) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
| JP2671257B2 (ja) * | 1995-07-13 | 1997-10-29 | エーザイ株式会社 | 溶解遅延性ゼラチン製剤組成物 |
| SE9702533D0 (sv) | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
| IN186245B (cs) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| EP2332522A3 (en) | 1998-03-19 | 2011-12-07 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| EP1245227A1 (en) * | 2001-03-31 | 2002-10-02 | Jagotec Ag | A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same |
| US20030203027A1 (en) * | 2002-04-26 | 2003-10-30 | Ethicon, Inc. | Coating technique for deposition of drug substance on a substrate |
| US20040086566A1 (en) * | 2002-11-04 | 2004-05-06 | Alpharma, Inc. | Waxy matrix dosage forms |
| US7485322B2 (en) * | 2002-12-24 | 2009-02-03 | Lek Pharmaceuticals D.D. | Modified release pharmaceutical composition |
| MXPA05008843A (es) * | 2003-02-21 | 2005-10-18 | Lek Pharmaceuticals | Sistema terapeutico que comprende amoxicilina y acido clavulanico. |
| WO2005046655A1 (en) * | 2003-11-04 | 2005-05-26 | Shire Laboratories, Inc. | Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms |
| BRPI0716481A2 (pt) * | 2006-09-04 | 2014-03-18 | Panacea Biotec Ltd | Tecnologia de liberação flutuante programável |
| WO2010020098A1 (zh) * | 2008-08-18 | 2010-02-25 | 北京天衡药物研究院 | 胃滞留药物释出系统及其制备方法和用途 |
| WO2009087665A2 (en) * | 2007-12-11 | 2009-07-16 | Vishwanath Sudhir Nande | Novel gastroretentive drug delivery system |
| GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| FR2945945B1 (fr) * | 2009-05-29 | 2011-07-29 | Flamel Tech Sa | Procede de preparation de particules creuses et leurs applications |
| FR2945947B1 (fr) | 2009-05-29 | 2011-07-29 | Flamel Tech Sa | Compositions pharmaceutiques flottantes a liberation controlee |
| WO2011004799A1 (ja) * | 2009-07-06 | 2011-01-13 | 杏林製薬株式会社 | 中空構造を有する錠剤 |
| US9314430B2 (en) | 2010-07-05 | 2016-04-19 | Jagotec Ag | Floating gastric retentive dosage form |
| MX2014000517A (es) * | 2011-07-14 | 2014-07-24 | Apet Holding B V | Composiciones de nicotinamida y el uso terapeutico de las mismas. |
| US10137094B2 (en) | 2011-10-11 | 2018-11-27 | Sun Pharmaceutical Industries Limited | Gastroretentive dosage system and process of preparation thereof |
| CA3149459A1 (en) * | 2012-07-16 | 2014-01-23 | APET Holding B.V. | Gastro-retentive drug delivery system |
| ES2536836T3 (es) | 2012-10-12 | 2015-05-29 | Omya International Ag | Formulación de medicamento gastrorretentivo y sistemas de liberación y su método de preparación usando carbonato de calcio transformado en funcional |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| CN106573015B (zh) | 2014-06-11 | 2021-11-26 | 麻省理工学院 | 肠溶弹性体 |
| EP3034070A1 (en) | 2014-12-18 | 2016-06-22 | Omya International AG | Method for the production of a pharmaceutical delivery system |
| CN104706613B (zh) * | 2015-03-20 | 2018-01-16 | 华侨大学 | 一种胃漂浮空心缓释片的制备方法 |
| EP3069713A1 (en) | 2015-03-20 | 2016-09-21 | Omya International AG | Dispersible dosage form |
| US10953208B2 (en) | 2015-05-01 | 2021-03-23 | Massachusetts Institute Of Technology | Triggerable shape memory induction devices |
| US11576859B2 (en) | 2015-10-23 | 2023-02-14 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| BR112018011636B1 (pt) | 2015-12-08 | 2024-03-12 | Lyndra Therapeutics, Inc | Sistema de residência gástrico para liberação sustentada de um agente terapêutico |
| WO2017158171A1 (en) * | 2016-03-18 | 2017-09-21 | Grünenthal GmbH | Floating pharmaceutical dosage form |
| AU2017268840B2 (en) | 2016-05-27 | 2022-02-10 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
| EP3269361A1 (en) | 2016-07-14 | 2018-01-17 | Omya International AG | Dosage form |
| CN118766834A (zh) | 2016-09-30 | 2024-10-15 | 林德拉治疗公司 | 用于金刚烷类药物缓释的胃驻留系统 |
| TWI811221B (zh) | 2017-06-09 | 2023-08-11 | 美商萊恩卓治療公司 | 具有釋放速率調節膜之胃的滯留系統 |
| WO2021176361A1 (en) * | 2020-03-02 | 2021-09-10 | Craft Health Pte Ltd | Method of manufacturing oral dosage forms for extended drug release |
| EP4008509B1 (de) * | 2020-10-14 | 2023-06-07 | Bichsel, Hannes | Geschäumte biogranulatkörner |
| WO2023166225A1 (en) * | 2022-03-04 | 2023-09-07 | APET Holding B.V. | Digestive enzyme formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3418999A (en) * | 1964-02-12 | 1968-12-31 | Donald W. Davis | Method of swallowing a pill |
| FR1454013A (fr) * | 1965-08-18 | 1966-07-22 | Pluripharm | Mode de présentation de deux médicaments associés |
| US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
-
1974
- 1974-03-12 JP JP2767374A patent/JPS5512411B2/ja not_active Expired
-
1975
- 1975-03-10 FR FR7507336A patent/FR2263744B1/fr not_active Expired
- 1975-03-10 BE BE154189A patent/BE826498A/xx not_active IP Right Cessation
- 1975-03-11 SE SE7502725A patent/SE409286B/xx not_active IP Right Cessation
- 1975-03-11 DE DE2510620A patent/DE2510620C2/de not_active Expired
- 1975-03-11 DK DK97875AA patent/DK142802B/da not_active IP Right Cessation
- 1975-03-11 ES ES435500A patent/ES435500A1/es not_active Expired
- 1975-03-11 US US05/557,408 patent/US3976764A/en not_active Expired - Lifetime
- 1975-03-12 NL NL7502952A patent/NL7502952A/xx not_active Application Discontinuation
- 1975-03-12 CA CA221,903A patent/CA1054056A/en not_active Expired
- 1975-03-12 GB GB10214/75A patent/GB1507521A/en not_active Expired
- 1975-03-12 CH CH315475A patent/CH604719A5/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003437A1 (en) * | 1984-02-10 | 1985-08-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
Also Published As
| Publication number | Publication date |
|---|---|
| SE409286B (sv) | 1979-08-13 |
| ES435500A1 (es) | 1977-02-01 |
| GB1507521A (en) | 1978-04-19 |
| DE2510620A1 (de) | 1975-09-18 |
| DE2510620C2 (de) | 1984-01-05 |
| FR2263744A1 (cs) | 1975-10-10 |
| DK97875A (cs) | 1975-09-13 |
| DK142802C (cs) | 1981-09-21 |
| FR2263744B1 (cs) | 1978-11-24 |
| JPS5512411B2 (cs) | 1980-04-02 |
| NL7502952A (nl) | 1975-09-16 |
| CH604719A5 (cs) | 1978-09-15 |
| US3976764A (en) | 1976-08-24 |
| JPS50121418A (cs) | 1975-09-23 |
| SE7502725L (cs) | 1975-09-15 |
| BE826498A (fr) | 1975-06-30 |
| CA1054056A (en) | 1979-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK142802B (da) | Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken. | |
| US5540945A (en) | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines | |
| EP0235718B1 (en) | Granule remaining in stomach | |
| FI78835C (fi) | Foerfarande foer framstaellning av en ny dipyridamol-retardform. | |
| US2928770A (en) | Sustained action pill | |
| US4587118A (en) | Dry sustained release theophylline oral formulation | |
| CA2342340C (en) | New sustained release oral formulations | |
| BE1004882A3 (fr) | Forme posologique pharmaceutique solide orale a liberation programmee. | |
| RU2477126C2 (ru) | Глюкозинолаты и бета-тиоглюкозидазы, покрытые энтеросолюбильной оболочкой | |
| US4935247A (en) | Composition for the oral administration of pharmaceuticals | |
| BG63152B1 (bg) | Дозирани форми с контролирано освобождаване на азитромицин | |
| US5277916A (en) | Tetracycline dosage form | |
| GB2101484A (en) | Oral dipyridamole compositions | |
| DK151608B (da) | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse | |
| PL188834B1 (pl) | Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji | |
| JPH0256418A (ja) | 新規医薬製剤およびその製造方法 | |
| JPS5859916A (ja) | ブロモヘキシンの遅延放出剤型およびその製造方法 | |
| Gohel | Modulation of active pharmaceutical material release from a novel ‘tablet in capsule system’containing an effervescent blend | |
| AU2013290875A1 (en) | Gastro-retentive drug delivery system | |
| EP1217992A1 (en) | Coated solid dosage forms | |
| EP0425699B1 (en) | Oral preparation which can be released at suitable region in intestine | |
| JPH0624962A (ja) | 腸溶徐放性製剤 | |
| AU684786B2 (en) | A drug delivery composition for alpha-adreno receptor blocking agents | |
| WO2020060426A1 (en) | An oral preparation containing sodium butyrate | |
| CN1216597C (zh) | 胃漂浮型脉冲释放胶囊 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |